Friday, February 20, 2009

NeuralStem Inc.'s ALS Trial on Clinical Hold

NeuralStem Inc.'s ALS Trial on Clinical Hold 2/20/2009
ROCKVILLE, Md., Feb. 20 /PRNewswire-FirstCall/ -- Neuralstem, Inc. announced today its spinal cord stem cell trial to treat ALS is on clinical hold and that the Federal Drug Administration (FDA) has provided the Company with specific comments, questions and recommendations for modifications to its protocol.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )
"The FDA has presented us with their review of our entire Investigational New Drug (IND) application," said Richard Garr, Neuralstem's President & CEO. "They have asked for some additional information regarding our product manufacturing process and pre-clinical studies, as well as our novel clinical delivery injection device and technique. The Company believes that it can provide this information in an expeditious manner."
"The Agency has also requested various modifications to the protocol and eligibility criteria for patients in the trial, as well as slight changes to the timing of the surgeries," Mr. Garr continued. "We are evaluating these changes and will respond accordingly. The Agency had extensive 'non hold' comments, requests for information, and recommendations. These primarily concerned issues that will need to be addressed for final product manufacturing and testing. We are appreciative of their work in this area."
"Over all we believe the Agency's comments and recommendations are extremely helpful," Garr concluded. "We are evaluating them carefully, and expect to reach agreement with the Agency on all matters so that the trial can be approved and move forward."
About Neuralstem
Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS).
In pre-clinical work, the company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10- KSB for the year ended December 31, 2007 and the quarterly report on form 10-Q for the period ended September 30, 2008.
CONTACT: Richard Garr, President of Neuralstem, Inc., +1- 301-366-4960; orMedia: Deanne Eagle of Planet Communications, +1-917-837-5866; orInvestors: Ina McGuinness of ICR, Inc., +1- 310-954-1100
Read at BioSpace.com

3 comments:

Anonymous said...

THE GOOD FOR NOTHING FUCKING DONOTHING ASSHOLES (FDA)

Anonymous said...

I couldn't have said it any better!!!!

梁爵 said...

2020.01.15台北酒店經紀人力銀行北部酒店工作開發部暨發展中心知名酒店經紀表示,以往上班族酒店兼差大多以門檻低、需要大量酒店小姐的酒店上班服務業為主,不過,隨著網路科技進步,八大行業就業酒店打工市場兼差型態也開始轉變,像是網紅、直播主首次擠入酒店上班從事酒店兼職工作的前5名。不過,許多年輕人要成為知名紅牌酒店小姐需要有創意、具備個人特色或是領域專業,也要具備國外接飯局(陪睡性交易)企劃、經過酒店經紀後製及行銷能力。酒店小姐要先吸睛,才有機會吸金。為了解上班族酒店兼職/大學生酒店兼差現況,酒店經紀人力銀行特別設計「台北風俗酒店經紀兼差現況調查」,酒店經紀2020年自1月1日到12月30日間進行網路亞洲大規模酒店上班問卷抽樣調查,有效樣本數為2000份,信心水準93%,誤差值為正負7.9個百分點